<DOC>
<DOCNO>
EP-0008559
</DOCNO>
<TEXT>
<DATE>
19800305
</DATE>
<IPC-CLASSIFICATIONS>
A61K-39/29 C12R-1/91 A61P-31/00 A61P-31/12 <main>C12N-7/08</main> C12N-7/00 
</IPC-CLASSIFICATIONS>
<TITLE>
live attenuated human hepatitis-a-virus, method for growing it in cell culture in vitro and composition comprising it.
</TITLE>
<APPLICANT>
merck & co incus <sep>merck & co. inc.<sep>merck &amp; co., inc. 126, east lincoln avenue p.o. box 2000 rahway new jersey 07065-0900us<sep>merck & co. inc. <sep>
</APPLICANT>
<INVENTOR>
hilleman maurice r<sep>provost philip j<sep>hilleman, maurice r.<sep>provost, philip j.<sep>hilleman, maurice r.4107 fields drivelafayette hill, pennsylvania 19444us<sep>provost, philip j.473 landis roadharleysville, pennsylvania 19438us<sep>hilleman, maurice r. <sep>provost, philip j.  <sep>hilleman, maurice r.4107 fields drivelafayette hill, pennsylvania 19444us<sep>provost, philip j.473 landis roadharleysville, pennsylvania 19438us<sep>
</INVENTOR>
<ABSTRACT>
hepatitis a virus is passaged at least once in a susceptible  sub-human primate; the infected liver from such passage is  used to inoculate an in vitro cell culture, the inoculated cell  culture is incubated until hepatitis a antigen is detected in the  cell sheet or culture fluid, and at least two serial in vitro  passages in cell culture are carried out.  the hepatitis a virus  so modified can be used to prepare live, attenuated hepatitis a  vaccine or an inactivated hepatitis a vaccine.  
</ABSTRACT>
</TEXT>
</DOC>
